Product Description
AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01741038)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Immunovative Therapies
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Inflammatory Breast Cancer|Melanoma|Prostate Cancer|Skin Cancer|Kidney Cancer|Lung Cancer|Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ITL-002-CRYO | P2 |
Completed |
Prostate Cancer|Kidney Cancer|Melanoma|Inflammatory Breast Cancer|Lung Cancer|Skin Cancer|Colorectal Cancer |
2011-03-01 |